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Background: Rotavirus is a leading worldwide cause of acute gastroenteritis in young children. This retrospective
hospital-based study assessed the burden of rotavirus gastroenteritis in children younger than 6 years in Japan.
Methods: Children admitted to eight hospitals for acute gastroenteritis between 2008 and 2009 were identified
from hospital admission databases. Diagnosis of acute gastroenteritis/rotavirus gastroenteritis and hospital-acquired
rotavirus gastroenteritis was confirmed based on either the International Classification of Diseases and Related
Health Problems 10th revision (ICD10) codes (intestinal infectious diseases [AA00-AA09] and rotavirus gastroenteritis
[A08.0]) or from rapid rotavirus diagnostic test results.
Results: Of 13,767 hospitalized children, 11.9% (1,644), 4.8% (665) and 0.6% (81) were diagnosed with acute
gastroenteritis, rotavirus gastroenteritis and hospital-acquired rotavirus gastroenteritis, respectively. Among acute
gastroenteritis hospitalizations, 40.5% (665/1,644; ICD10 and rapid test) and 57.7% (645/1,118; rapid test only) were
confirmed as rotavirus positive. Of 1,563 children with community-acquired acute gastroenteritis, 584 (37.4%) cases
were confirmed as rotavirus positive. The median durations of hospitalization for all and community-acquired
rotavirus gastroenteritis were 5.0 days (range: 2.0−133.0 days) and 5.0 days (range: 2.0-34.0 days), respectively.
Among rotavirus gastroenteritis hospitalizations, 12.2% (81/665) of cases were hospital-acquired and the median
duration of hospitalization was 10.0 days (range: 2.0-133.0 days). The median duration of additional hospitalization
due to hospital-acquired rotavirus gastroenteritis was 3.0 days (range: 0–14 days). The overall incidence rate of
hospital-acquired rotavirus gastroenteritis was 1.0 per 1,000 children hospital-days. The number of rotavirus
gastroenteritis cases peaked between February and May in both 2008 and 2009, and the highest number of cases
was reported in March 2008 (21.8%; 145/665). The highest number of rotavirus gastroenteritis hospitalizations
(24.1%; 160/665) was observed in children aged 12–18 months. The proportion of hospital-acquired rotavirus
gastroenteritis was higher in children aged below 18 months as compared to children at least 18 months of age
(0.94 [95% CI: 0.71-1.21] vs. 0.39 [95% CI: 0.25-0.58]) and for children hospitalized for at least 5 days compared to
those hospitalized for less than 5 days (0.91 [95% CI: 0.72-1.14] vs. 0.15 [95% CI: 0.05-0.32]).
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Conclusions: Both community- and hospital-acquired rotavirus gastroenteritis are significant public health
problems in Japan. Data from this study justify the need for the introduction and implementation of rotavirus
vaccination in the Japanese national immunization program.
Trial registration: ClinicalTrials.gov, NCT01202201
Keywords: Children, Epidemiology, Gastroenteritis, Japan, Hospital-acquired, RotavirusBackground
Rotavirus (RV) is the most common etiological cause of
acute gastroenteritis (GE) resulting in hospitalization
among young children throughout the world [1]. In
Japan, the burden of RVGE disease is substantial, with
approximately 800,000 children aged below 6 years visit-
ing clinics and hospital outpatient departments annually.
A previous study conducted in Japan reported an overall
incidence of outpatient visits of 11 cases per 100 person-
years due to RVGE in children less than 6 years of age;
the highest incidence (27 cases per 100 person-years)
was observed in infants [2]. In another single-center
study conducted between 2008 and 2010 in Kyoto, the
proportion of children aged below 5 years diagnosed
with RVGE was reported to be 56% [3]. Although epi-
sodes of RVGE can potentially be severe [4], due to a
low mortality rate associated with RVGE in Japan, local
awareness of the disease is low. Nevertheless, in Japan,
RVGE is a common cause of acute GE hospitalizations
whether community- or hospital-acquired and results in
significant clinical and economic burden [5].
There are no official, evidence-based guidelines on the
treatment of pediatric acute GE in Japan [6], but RVGE
is most commonly managed using intravenous fluid re-
placement therapy [7]. Prophylactic interventions, such
as RV vaccination, may represent an effective primary
public health strategy to reduce the burden of RVGE [8].
Two orally administered RV vaccines, which have demon-
strated good efficacy and safety profiles in global clinical
trials, have been licensed in most countries: Rotarix™
(GlaxoSmithKline Vaccines, Belgium) and RotaTeq® (Merck
and Co., Inc., Whitehouse Station, NJ, USA) [8,9]. In 2009,
the World Health Organization (WHO) recommended the
inclusion of RV vaccines in the routine childhood vaccine
programs of all countries [9].
The objectives of this study were to estimate the bur-
den of overall acute GE, RVGE and hospital-acquired
RVGE in hospitalized children younger than 6 years of
age, as well as to assess the age and seasonal distribu-
tions; and duration of hospitalization and additional
hospitalization associated with hospital-acquired RVGE.
Our findings could have important implications for the
introduction of routine RV vaccination into the Japanese
national immunization program. Furthermore, up to-
date epidemiological data on RVGE disease may helpevaluate the impact and cost-effectiveness of RV vaccin-
ation programs in Japan.Methods
Study design
This retrospective, multi-center epidemiological study
was conducted between January 2008 and December
2009 at eight regional core hospitals in the urban areas
of Japan, which represented an optimum geographic
coverage (Figure 1). All study hospitals treated pediatric
infectious diseases including acute GE, and were in-
cluded if they had at least 15 pediatric inpatient beds
(range in the study hospitals 16–50) and routinely tested
for the presence of RV using rapid tests. At each hos-
pital, one nurse was allocated to either seven or ten chil-
dren and participating hospitals provided primary,
secondary and tertiary emergency care for children [10].
Children aged less than 6 years, who were hospitalized
for acute GE or RVGE during the survey period, were
included in the study. These children were identified
through the electronic hospital databases. Diagnosis of
acute GE/RVGE and hospital-acquired RVGE was con-
firmed either according to the International Classifica-
tion of Diseases and Related Health Problems 10th
revision (ICD 10) codes (intestinal infectious diseases
[AA00-AA09] and RVGE [A08.0]) or based on the re-
sults from rapid RV diagnostic tests, using immune-
chromatography (RapidTesta®ROTA-ADENO, Orion
Diagnostica; Bioline SD Rota/Adeno Rapid, Standard
Diagnostics, INC, Kyonggi, Korea; BD Rota/Adeno
Examan™ stick, Becton, Dickinson & Co; and Premier™
Rotaclone®, Meridian Bioscience, Inc, Ohio, USA).
Acute GE was based on the ICD 10 codes for intestinal
infectious diseases: with occurrence of diarrhea for less
than 14 days. Community-acquired RVGE was defined
as RVGE hospitalization other than hospital-acquired
RVGE. Hospital-acquired RVGE was defined as occur-
rence of RVGE at least 48 hours after hospital admission
or within 48 hours after hospital discharge. For a child
who was hospitalized for acute GE within the last 48
hours investigators ascertained the presence of RV from
the medical chart. RV tests were not performed in hospi-
tals for subjects who had already been diagnosed with
RVGE at other clinics or hospitals, since the variance of
Figure 1 Geographic distribution of the participating hospitals, 2008–09.
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participating hospitals.
Medical histories were collected from medical charts or
the hospital database, and the duration of hospitalization
for acute GE and community-acquired RVGE, define as
the number of days between the date of admission and
date of discharge, was automatically calculated in the
medical chart database. The duration of additional
hospitalization for hospital-acquired RVGE (in days) was
estimated as the difference between the usual average
number of days spent in hospital due to the specific med-
ical condition and the number of days the child actually
spent in hospital.
This study was conducted in compliance with Good
Clinical Practice (GCP) guidelines and the Japanese
Ministry of Health, Labor and Welfare’s (MHLW) ethical
guidelines for epidemiological research. Since this was
an observational survey using hospital database data, in-
formed consent was not obtained from the enrolled sub-
jects. This is in accordance with the Japanese ethical
guidelines for epidemiological research. All the relevant
documents were reviewed by the ethical committees and
ethical approval was sought from each of the participat-
ing hospitals.Endpoints and statistical analysis
All analyses were descriptive and the demographic dis-
tribution of children aged below 6 years who were hospi-
talized with acute GE, RVGE and hospital-acquired
RVGE were presented. The overall proportions of acute
GE, RVGE and hospital-acquired RVGE among all the
subjects and proportions of hospital-acquired RVGE
stratified by hospital and patient characteristics were es-
timated with 95% confidence intervals (CI) using the
Exact Method [11]. Median duration of hospitalization
(in days) due to RVGE, community-acquired RVGE and
hospital-acquired RVGE, and the median duration of add-
itional hospitalization due to hospital-acquired RVGE
were estimated. The incidence of hospital-acquired RVGE
was calculated by dividing the number of hospital-
acquired RVGE cases by the total number of hospital days
among all at-risk children and was expressed per 1000
hospital days. When estimating incidence, 95% CI was cal-
culated using Poisson’s method. All statistical analyses
were performed using SAS version 9.2.
Results
Among 13,767 hospitalized children, 1,648 were diag-
nosed with acute GE and were included in the study, of
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did not meet the inclusion criteria. The demographic
characteristics of the 1,644 (11.9%) children included in
the final analysis are shown in Table 1.
Among the 1,644 children with acute GE, 665 (40.5%)
were confirmed with RV, using either ICD 10 diagnostic
codes or RV diagnostic tests. The proportion of overall
RVGE among all hospitalized children aged less than 6
years was therefore 4.8% (665/13,767). RV diagnostic
testing, performed on stool samples from 1,118 children
(68.0%) with acute GE, confirmed that 645 (57.7%) were
RV-positive. Of the 1,563 children with community-
acquired acute GE, 584 (37.4%) were RV-positive. Eighty-
one of the 665 RV-positive cases, (12.2%) were confirmed
as hospital-acquired RVGE. Similar proportions of RVGE
(overall and hospital-acquired) were observed in children
aged less than 5 years (Table 2). Underlying medical
conditions were present in 159 cases (9.7%) of acute
GE hospitalizations, 59 cases (8.9%) of RVGE hospitali-
zations and 22 cases (27.2%) of hospital-acquired
RVGE cases (Table 1).
Cumulative age distributions of acute GE and RVGE
hospitalizations are shown in Figure 2. Three cases of
RVGE were reported in infants aged below 1 month.
The highest proportion of acute GE and RVGE hospitali-
zations were observed in children aged 12–18 months
(20.2% [332/1,644] and 24.1% [160/665], respectively),
followed by children aged 6–12 months (18.0% [296/
1,644] and 16.6% [110/665], respectively).
The median duration of hospitalization for all RVGE
and community-acquired RVGE was 5.0 days (range:
2.0−133.0 days) and 5.0 days (range: 2.0−34.0 days).
The longest duration of hospitalization due to all
RVGE (median 9.0 days [range: 5.0−108.0 days]) was
observed in children aged 5–6 months (n/N= 7/665).Table 1 Demographic characteristics of children aged less tha
Subject group Acute GE2 (N =16
Gender (male/female) (%) 57.0/43.0
Age (months) Mean ± SD1 24.6 ± 18.07
Median (range) 19 (0–71)
Underlying medical condition n (%) 10 (0.6)
-Cardiac disease 14 (0.9)
- Gastrointestinal disease 20 (1.2)
-Neurological disease 15 (0.9)
-Prematurity 46 (2.8)
-Pulmonary disease 54 (3.3)
-Others 1485 (90.3)
- No condition
Note: 1Standard deviation; 2Acute gastroenteritis; *Information on hospitalization dThe number of RVGE cases peaked between February
and May in both 2008 and 2009 and the highest number
of cases (21.8%; 145/665) was recorded in March 2008.
Among the children aged below 6 years who were hospi-
talized, the overall proportion of hospital-acquired RVGE
was estimated to be 0.6% (N=81; 95% CI: 0.5−0.7) (0.9%
[95% CI: 0.7−1.1] in 2008 and 0.3% [95% CI: 0.2−0.5] in
2009). Across the hospitals, the proportions of hospital-
acquired RVGE ranged from 0.1% (95% CI: 0.0−0.7) to
1.7% (95% CI: 1.1−2.6). The overall incidence of hospital-
acquired RVGE was 1.0 per 1,000 person-days (95% CI:
0.8−1.2) in children aged less than 6 years (1.4 [95%
CI: 1.1−1.8] in 2008 and 0.5 [95% CI: 0.3−0.8] in 2009).
The highest number of hospital-acquired RVGE cases
was observed in children aged 12–18 months (27.2%;
22/81), followed by those aged 0–6 months (23.4%; 19/81)
and 6–12 months (19.7%; 16/81) (Figure 2). All three cases
of RVGE in infants aged below 1 month and 50.0% (3/6)
of cases in children aged less than 2 months were
hospital-acquired. A decreasing trend of hospital-acquired
RVGE among RVGE hospitalizations with age was ob-
served, with higher proportions being reported in younger
children (especially in infants aged below 1 month)
(Figure 2).
The median duration of hospitalization for hospital-
acquired RVGE cases was 10.0 days (range: 2.0−133.0), but
varied according to the presence of different medical condi-
tions: gastrointestinal disease (26.0 days [range: 26.0−26.0]);
neurological disease (108.0 days [range: 23.0−133.0]); pre-
maturity (31.0 days [25.0−37.0]); pulmonary disease (10.0
days [range: 7.0−15.0]); and others (20.5 days [range:
12.0−89.0]). In subjects without any underlying med-
ical condition, the median duration was 9.0 days (range:
2.0−43.0). The median duration of hospitalization for chil-
dren with hospital-acquired RVGE also varied by hospitaln 6 years, hospitalized in Japan during 2008–09
44) RVGE (N=665) Hospital-acquired RVGE (N=81)
54.6/45.4 61.7/38.3
23.1 ± 15.88 15.9 ± 13.84
18 (0–71) 13 (0–62)
5 (0.8) 0 (0.0)
2 (0.3) 1 (1.2)
8 (1.2) 3 (3.7)
6 (0.9) 2 (2.5)
18 (2.7) 8*(9.9)
20 (3.0) 8 (9.9)
606 (91.1) 59 (72.8)
uration missing for one case.
Table 2 Proportion of RVGE diagnosed in hospitalized children (ICD10 codes and RV rapid test kits) in Japan during
2008–09
Age group Proportion of RVGE
among all hospitalizations
(n/N; 95% CI)
Proportion of RVGE among
all acute GE hospitalizations
(n/N; 95% CI)*
Proportion of hospital-acquired
RVGE among RVGE (n/N; 95% CI)
Based on ICD code and kit
results
Based on kit test results
<2 years1 4.9% (409/8285; 4.5−5.4) 41.2% (409/993; 38.1−44.3) 55.0% (398/723; 51.3−58.7) 15.2% (62/409; 11.8−19.0)
2−<4years 5.8% (191/3265; 5.1−6.7) 47.6% (191/401; 42.6−52.6) 69.7% (186/267; 63.8−75.1) 7.9% (15/191; 95% CI: 4.5−12.6)
4−<6 years 2.9% (65/2213; 2.3−3.7) 26.0% (65/250; 20.7−31.9) 47.2% (60/127; 38.3−56.3) 6.2% (4/65; 95% CI: 1.7−15.0)
<5 years2 5.0% (643/12771; 4.7−5.4) 41.7% (643/1542; 39.2−44.2) 58.3% (625/1072; 55.3−61.3) 12.4% (80/643; 10.0−15.2)
<6 years3 4.8% (665/13767; 4.5−5.2) 40.5% (665/1644; 38.1−42.9) 57.7% (645/1118; 54.7−60.6) 12.2% (81/665; 9.8−14.9)
Note: 1<2 is due to the highest disease burden in this age group; 2<5 is to make it possible to compare with the result from other developed countries; 3<6 years
is to align with Japanese schooling system (children start elementary education at the age of 6 years).
*Both indicate the same proportion.
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(range: 15.0−26.0). The median duration of additional
hospitalization as a result of hospital-acquired RVGE was
3.0 days (range: 0.0–14.0).
The proportion of hospital-acquired RVGE was higher
in children aged below 18 months as compared to chil-
dren at least 18 months of age (0.94 [95% CI: 0.71−1.21]
vs. 0.39 [95% CI: 0.25−0.58]) and for children hospital-
ized for at least 5 days compared to those hospitalized
for less than 5 days (0.91 [95% CI: 0.72−1.14] vs. 0.15
[95% CI: 0.05−0.32]). The proportions of hospital-
acquired RVGE were also estimated to be higher in hos-
pitals: with an allocation of one nurse per seven patients
compared to those with an allocation of one nurse per
ten patients (0.74 [95% CI: 0.56−0.95] vs. 0.18 [95% CI:
0.04−0.54]); with at least 30 beds compared to fewer
than <30 beds (0.74 [95% CI: 0.58−0.92] vs. 0.53 [95%Age (months)






















Figure 2 Age distribution of acute GE, RVGE hospitalizations and hosCI: 0.34−0.79]); and in hospitals with an isolation ward
(0.75 [0.59−0.94] vs. 0.24 [95% CI: 0.08−0.56]) compared
to hospitals without an isolation ward) (Table 3). Among
all the children with RVGE and an underlying medical
condition 37.3% (22/59) cases were hospital-acquired
RVGE compared to only 9.7% (59/606) of cases in chil-
dren who did not have any underlying medical condition.
Discussion
The present study is one of the largest multicenter hospital-
based studies conducted in Japan that describes the burden
of RVGE disease, including hospital-acquired RVGE in pre-
school children. The findings of this study estimate that
4.8% of all hospitalizations in children aged below 6 years
are due to RV. Despite the retrospective study design, 68.0%
of hospitalizations due to acute GE were tested for the pres-
ence of RV of which 57.7% cases were RV-positive with theAge (months)

















 % AGE for each specific age group
d as % RVGE for each specific age group
tion of AGE hospitalizations (N =1644)
tion of RVGE hospitalizations (N = 665)
ion of HA RVGE cases (N = 81)
pital-acquired RVGE cases.
Table 3 Characteristics of hospital-acquired RVGE in
children aged below 6 years in Japan during 2008–09
(N=13767)
Characteristics Categories N n % (95% CI)
Age at the time of
hospitalization
≥18 months 6125 24 0.39 (0.25−0.58)
<18 months 6075 57 0.94 (0.71−1.21)
Hospitalization
duration1
≥5 days 8128 74 0.91 (0.72−1.14)
<5 days 4053 6 0.15 (0.05−0.32)
missing 19 1 5.26 (0.13−26.03)
Nurse allocation┼ N* =7 10573 78 0.74 (0.58−0.92)
N* =10 1627 3 0.18 (0.04−0.54)
Number of beds┼ ≥30 7854 58 0.74 (0.56−0.95)




With 10122 76 0.75 (0.59−0.94)
Without 2078 5 0.24 (0.08−0.56)
1Cut-off point of 5 days was decided based on mean hospitalization duration in
Japanese infectious pediatric wards (4.7 days for children aged 1–4 years) [21].
Note: *1 nurse per 7/10 patients; N: number of all hospitalizations <6 years of
age in the given category who are at risk of acquiring hospital-acquired RVGE;
n: number of hospital-acquired RVGE subjects.
┼Hospital data: Number of hospitals with N*=7: 6 hospitals and N*=10: 2
hospitals; Number of hospitals with ≥30 beds and <30 beds: 4 hospitals;
Number of hospitals with isolation ward/room: 6 hospitals and without an
isolation ward/room: 2 hospitals.
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vations are consistent with previously published data on
RVGE from Japan [7]. In this study, the highest burden of
hospitalized RVGE disease was observed in children youn-
ger than 2 years of age, which is similar to that reported
from several observational studies conducted in Europe
[12-15]. The occurrence of RVGE usually exhibits a seasonal
pattern [16] and in this study, a peak in the number of
RVGE cases was observed between February and May in
both 2008 and 2009. The highest number of RVGE cases
was observed in March, suggesting that in line with previous
reports, RVGE is a common disease in Japan until early
summer and is no longer winter-specific [17,18].
We found that the proportion of hospital-acquired
RVGE among all hospitalizations of children aged less
than 6 years was 0.6% and was associated with median
duration of additional hospitalization of 3 days. This pro-
portion was well within the range that was observed in
children below 5 years in the European Union (0.3−27.7%)
[19]. We believe that this relatively low proportion of
hospital-acquired RVGE could be due to different infec-
tion control procedures in the Japanese healthcare system
[20]. However, there are no differences between Japanese
and European hospitals and the reason for this apparent
difference remains to be unknown. The incidence of
hospital-acquired RVGE of 1.0 per 1,000 hospital-days
reported in our study was well within the range (0.0−1.87
per 1,000 days of hospitalization) reported in Europe byForster et al. [13]. In other observational studies
conducted across Europe, it was reported that 95.7% of all
hospital-acquired RVGE cases occurred in children youn-
ger than 2 years of age [13]. Our results also recorded
higher proportions of hospital-acquired RVGE in children
below 2 years of age compared with older children.
The median duration of addition hospitalization due to
hospital-acquired RVGE of 3.0 days which we observed
was slightly lower than the mean duration of
hospitalization (4.7 days) in infectious disease wards
among children aged 1–4 years in Japan [21].
This study provides signs of patient and hospital char-
acteristics that may be associated with the occurrence of
hospital-acquired RVGE. Patient characteristics such as
duration of hospitalization, age, prematurity or low
birth-weight, severe immuno-deficiencies and absence/
presence of underlying medical conditions have been
previously reported as risk factors for hospital-acquired
RV infection [19]. Indeed, in our study children with
underlying medical conditions had a higher proportion
of hospital-acquired RVGE compared to children with-
out these conditions. We found higher proportions of
hospital-acquired RVGE in children aged below 18
months and in those who were hospitalized for at least 5
days compared to those aged at least 18 months or hos-
pitalized for fewer than 5 days, respectively. Children
younger than 18 months of age may be more susceptible
to hospital-acquired RVGE as well as need more atten-
tion from caregivers and may therefore be more likely to
acquire RV infection from them. The proportions of
hospital-acquired RVGE were higher in children at hos-
pitals with a nurse allocation of one per seven patients
than at hospitals with an allocation of one per ten pa-
tients, and also in hospitals with an isolation ward/room.
The observation associated with higher nurse allocation
may be related to the fact that nurses may be considered
as reservoirs of RV infection. However, this study was
not designed specifically to study the association of hos-
pital characteristics and occurrence of hospital-acquired
RVGE, presented in previous studies [19], therefore the
clinical implications of these data need to be interpreted
with caution.
The direct medical cost of a single hospitalization with
a mean duration of hospitalization of 5.4 days due to
RVGE in Japan has been estimated to be 1,888 US$
(221,000 JPY; 1 US$ = 83.6 JPY [22]) [3]. Considering
the median duration of a single RVGE hospitalization of
5.0 days in this study, the direct medical cost per RVGE
case per day is estimated to be 378 US$. Accordingly,
the direct medical cost for an additional 3.0 days of
hospitalization due to hospital-acquired RVGE in this
study is estimated to be 875 US$ per hospital-acquired
RVGE case. By extrapolating data from Nakagomi et al.
[7], 78,000 RVGE hospitalizations were estimated in
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which 12.4% (9,672/78,000) could be considered as
hospital-acquired RVGE cases per year. Therefore, the
nationwide cost for hospital-acquired RV infection is es-
timated to be as high as 8,466,341 US$ per year in
Japan.
There are several reasons why the results of this study
may be applied to the general Japanese pediatric population
below 6 years of age hospitalized for acute GE. This is the
largest multi-hospital study yet conducted, including 8 hos-
pitals across Japan capturing ~0.5% of the total RVGE hos-
pitalizations that are expected to be reported in children
younger than 6 years of age every year [7]. In addition, this
study obtained laboratory confirmation using rapid RV
diagnostic testing for 68.0% of all acute GE cases, which
minimized the possible misclassification of RVGE. The
data from this study allow for real world estimates of
hospital-acquired RVGE and the duration of additional
hospitalization due to hospital-acquired RVGE. Indeed,
the hospital databases used in this study confirmed the
good quality and diagnostic accuracy. Moreover, the data
reported here are consistent with previous studies [3,7,23].
Besides the inevitable limitations of all retrospective
surveillance studies [24], several specific limitations also
need to be considered when interpreting the results of
this study. Some of the RVGE cases did not have a RV
rapid test recorded in the medical chart (~32%), which
we believe was due to the fact that testing for the pres-
ence of RV may have been conducted previously in other
clinics or hospitals. However, these subjects had the spe-
cified ICD 10 code for RVGE recorded in hospital data-
base. Furthermore, the number of hospital-acquired
RVGE cases may have been underestimated in this study
due to missing ICD 10 codes for some RVGE cases and
the difficulty of capturing data on the onset of hospital-
acquired RVGE within 48 hours of discharge from hos-
pital, unless the children returned to the participating
hospitals for subsequent treatment. Since this was a
retrospective database study, no diagnostic criteria were
used as confirmation of diagnosis. The diagnosis was
based on clinical practice and results of the RV diagnos-
tic rapid tests were taken from the medical charts. Our
method of determining median duration of additional
hospitalization for hospital-acquired RVGE did not take
into account the potential impact of accompanying
chronic medical conditions and this may thus limit the
generalizability of our findings. Another limitation of the
present analysis is that although subjective, the duration
of additional hospitalization for hospital-acquired RVGE
was estimated based on careful examination of the med-
ical chart and prescription record by comparing the dur-
ation of hospitalization for the specific case and the
usual average duration of hospitalization for certain
diseases if not associated with RVGE. However,duration of additional hospitalization was estimated as
zero if medical chart review revealed that RV was un-
likely to have had any impact on hospitalization dur-
ation (e.g. duration of hospitalization due to primary
diagnoses was too long and hospital-acquired RVGE
occurred in the middle of hospitalization for initial
diagnoses etc.). Finally, the incidence calculated in this
study may have been underestimated since the incubation
period for hospital-acquired RV infection was not taken
into account.
Conclusions
The results of this large, multicenter study conducted in
Japanese hospitals suggest that RV is a major cause of
acute GE disease in children younger than 6 years of age
and leads to a substantial burden on the public
healthcare system in Japan. These results warrant further
investigation into the need for implementing RV vaccin-
ation into the national immunization program of Japan.
The baseline data from this study will be useful when
assessing the impact and cost-effectiveness of future RV
vaccination programs.
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